rs143777403
Positions:
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 2P and 8B. PM1BP4_StrongBS2
The NM_213599.3(ANO5):c.155A>G(p.Asn52Ser) variant causes a missense change. The variant allele was found at a frequency of 0.00273 in 1,613,408 control chromosomes in the GnomAD database, including 9 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.0024 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0028 ( 9 hom. )
Consequence
ANO5
NM_213599.3 missense
NM_213599.3 missense
Scores
1
3
15
Clinical Significance
Conservation
PhyloP100: 6.14
Genes affected
ANO5 (HGNC:27337): (anoctamin 5) This gene encodes a member of the anoctamin family of transmembrane proteins. The encoded protein is likely a calcium activated chloride channel. Mutations in this gene have been associated with gnathodiaphyseal dysplasia. Alternatively spliced transcript variants have been described. [provided by RefSeq, Nov 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -6 ACMG points.
PM1
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 9 uncertain in NM_213599.3
BP4
Computational evidence support a benign effect (MetaRNN=0.037495136).
BS2
High AC in GnomAd4 at 367 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ANO5 | NM_213599.3 | c.155A>G | p.Asn52Ser | missense_variant | 4/22 | ENST00000324559.9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ANO5 | ENST00000324559.9 | c.155A>G | p.Asn52Ser | missense_variant | 4/22 | 1 | NM_213599.3 | P2 |
Frequencies
GnomAD3 genomes AF: 0.00241 AC: 367AN: 152014Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
367
AN:
152014
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00215 AC: 541AN: 251140Hom.: 2 AF XY: 0.00220 AC XY: 299AN XY: 135742
GnomAD3 exomes
AF:
AC:
541
AN:
251140
Hom.:
AF XY:
AC XY:
299
AN XY:
135742
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00276 AC: 4033AN: 1461276Hom.: 9 Cov.: 32 AF XY: 0.00278 AC XY: 2020AN XY: 726940
GnomAD4 exome
AF:
AC:
4033
AN:
1461276
Hom.:
Cov.:
32
AF XY:
AC XY:
2020
AN XY:
726940
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00241 AC: 367AN: 152132Hom.: 0 Cov.: 32 AF XY: 0.00219 AC XY: 163AN XY: 74354
GnomAD4 genome
AF:
AC:
367
AN:
152132
Hom.:
Cov.:
32
AF XY:
AC XY:
163
AN XY:
74354
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
15
ALSPAC
AF:
AC:
13
ESP6500AA
AF:
AC:
2
ESP6500EA
AF:
AC:
31
ExAC
AF:
AC:
231
Asia WGS
AF:
AC:
2
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:7Benign:4
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Pathogenic:1Uncertain:4Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | May 03, 2018 | - - |
Likely pathogenic, flagged submission | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Oct 23, 2020 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2024 | ANO5: PM3:Strong, PM2:Supporting, BP4 - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Dec 21, 2020 | This variant is associated with the following publications: (PMID: 22980763, 23041008, 26810512, 31931849, 32419263, 25891276, 26911675, 25326637, 23606453, 30564623, 30919934, 31517061) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Mar 29, 2023 | Available data are insufficient to determine the clinical significance of the variant at this time. The frequency of this variant in the general population is higher than would generally be expected for pathogenic variants in this gene (http://gnomad.broadinstitute.org). In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Aug 31, 2021 | - - |
not specified Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 18, 2022 | Variant summary: ANO5 c.155A>G (p.Asn52Ser) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.0022 in 251140 control in the gnomAD v2 database, including 2 homozygotes. Additionally, the variant allele was observed predominantly at a frequency of 0.0048 within the Latino subpopulation at in the gnomAD v3 database (genomes data). The observed variant frequency within Latino control individuals in the gnomAD v3 database is over one fold of the estimated maximal expected allele frequency for a pathogenic variant in ANO5 causing Limb-Girdle Muscular Dystrophy, Autosomal Recessive (0.0048 vs 0.0047), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Latino origin. c.155A>G has been reported in the literature in individuals affected with Limb-Girdle Muscular Dystrophy, Autosomal Recessive (Sarkozy_2012, Sarkozy__2013, Wahbi_2013, Lee_2014, Savarese_2015, Nallamilli_2018, Ten Dam_2019, Mair_2020). These reports do not provide unequivocal conclusions about association of the variant with Limb-Girdle Muscular Dystrophy, Autosomal Recessive. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Ten ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance (n=7), benign (n=1), likely benign (n=1) and likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as likely benign. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genomic Research Center, Shahid Beheshti University of Medical Sciences | Jan 01, 2019 | - - |
Gnathodiaphyseal dysplasia Uncertain:1Benign:1
Benign, criteria provided, single submitter | clinical testing | Dr.Nikuei Genetic Center | Jun 29, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
ANO5-Related Muscle Diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Aug 24, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Gnathodiaphyseal dysplasia;C1969785:Autosomal recessive limb-girdle muscular dystrophy type 2L Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 26, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
T
M_CAP
Benign
D
MetaRNN
Benign
T
MetaSVM
Benign
T
MutationAssessor
Benign
L
MutationTaster
Benign
D
PrimateAI
Benign
T
PROVEAN
Benign
N
REVEL
Benign
Sift
Benign
T
Sift4G
Benign
T
Polyphen
D
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at